Physician profile
Andrea Ramirez
NPI 1003015108
$2,111.51
in general payments reported to CMS, 2019-2025
28 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $452 · 2023: $671 · 2024: $491 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $431.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $323.89 | 2022-2025 | |
| Corcept Therapeutics | $241.55 | 2022-2024 | Korlym |
| Novo Nordisk INC | $194.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $148.44 | 2025 | Fintepla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.31 | 2023-2025 | Jardiance |
| Shield Therapeutics INC | $90.85 | 2022-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.22 | 2022-2024 | Xifaxan, Trulance, Cycloset |
| Sanofi-Aventis U.S. LLC | $64.88 | 2022-2023 | |
| Amgen INC. | $49.36 | 2022-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $44.59 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $38.33 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $37.07 | 2022-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $29.32 | 2025 | Airsupra |
| Insulet Corporation | $24.39 | 2023 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.17 | 2022 | |
| Madrigal Pharmaceuticals | $21.81 | 2024 | Resmetirom |
| Idorsia Pharmaceuticals US INC | $19.79 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $18.84 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $17.28 | 2025 | Auvelity |
| Ascendis Pharma Endocrinology INC | $16.65 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $16.45 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.28 | 2023 | Prehevbrio |
| Kowa Pharmaceuticals America, INC. | $14.69 | 2023 | Seglentis |
| Sumitomo Pharma America, INC. | $14.39 | 2025 | Gemtesa |
| Lexicon Pharmaceuticals, INC. | $14.02 | 2023 | Inpefa |
| Paratek Pharmaceuticals, INC. | $13.04 | 2023 | Nuzyra |
| Esperion Therapeutics, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.